



下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEOliceridine hydrochlorideCat. No.: HY-16655ACAS No.: 1401031-39-7Synonyms: TRV130 (hydrochloride)分式: CHClNOS分量: 423.01作靶點: Opioid Receptor作通路: GPCR/G Protein; Neuronal Signaling儲存式: 4C, stored under nitrogen* In solvent : -80C,
2、6 months; -20C, 1 month (stored undernitrogen)溶解性數(shù)據(jù)體外實驗 DMSO : 38 mg/mL (89.83 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.3640 mL 11.8201 mL 23.6401 mL5 mM 0.4728 mL 2.3640 mL 4.7280 mL10 mM 0.2364 mL 1.1820 mL 2.3640 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備
3、液,并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Oliceridine hydrochloride (TRV130 hydrochloride)是新穎的 MOR 激動劑,能夠優(yōu)先激活 G-protein 信號通路,對 -arrestin 的作稍弱。體外研究 Oliceridine (TRV130) elicits robust G protein signaling, with potency and efficacy similar to morphine, but withfar less -arrestin recruitment and receptor
4、 internalization 2.1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE體內(nèi)研究 Oliceridine (TRV130) treatment produces robust antinociception, complete inhibition of gastrointestinalfunction, and weak abuse-related effects in mice 1. Oliceridine (TRV130) displays an ED50 of 0.9 mg/kg inan analgesic assay.
5、 Oliceridine analgesia is reversible in mice by administration of 3 mg/kg naloxone s.c. 15minutes after Oliceridine dosing. In the rat 52C hot plate, Oliceridine is 10-fold more potent than morphinewith ED50 of 0.32 and 3.2 mg/kg, respectively. Oliceridine (0.3 mg/kg, s.c.) possesses an improvedther
6、apeutic index of analgesia to constipation relative to morphine in mice 2. Oliceridine (TRV130; 1.2mg/kg, s.c.) significantly depresses respiration of mice 3.PROTOCOLKinase Assay 2 Equilibrium binding of unlabeled compounds is measured by inhibition of radioligand binding (3H-diperenorphine) to HEK
7、cell membranes expressing human MOR, KOR, and DOR. Unlabeled ligand andbuffer (50 mM Hepes, 5 mM MgCl2, 1 mM EGTA and 0.05% bovine serum albumin, pH 7.2, at 23C)containing radioligand are added to polypropylene 96-well plates. Assays are initiated by the addition ofmembrane (5-10 g protein/well) sus
8、pension. The concentration of 3H-diprenorphine (specific activity 50-52Ci/mmol), is 0.5-1 times the independently determined Kd. Compounds are diluted in DMSO and tested at afinal concentration of 1% DMSO. Nonspecific binding is defined in the presence of 1 M naloxone.Competition assays are performe
9、d at 23C for 3-4 hours to allow adequate time for equilibrium binding. In allassays, total radioligand bound to the filter is less than 10% of the total radioligand added. The separation ofbound from free radioligand is accomplished by rapid vacuum filtration of the incubation mixture over GF/Bfilte
10、r mats using a Brandel cell harvester. Filters are washed 2 times with 0.5 mL of ice-cold phosphatebuffered saline pH 7.0 containing 0.01% Triton 100. Radioactivity on the filters is quantified using aMicroBeta TriLux Liquid Scintillation Counter.MCE has not independently confirmed the accuracy of t
11、hese methods. They are for reference only.Animal Analgesia-like responses in are measured using a hotplate analgesia meter with dimensions of 29.2 26.7Administration 3 cm with mice restricted to a cylinder 8.9 cm in diameter and 15.2 cm high. Response is measured byrecording the latency to lick, flu
12、tter, or splay hind paw(s), or an attempt to jump out of the apparatus at 55 C,with a maximum cut-off time of 30 s. Once a response is observed or the cut-off time had elapsed, thesubject is immediately removed from the hotplate and placed back in its home cage. The animals areacclimated to the hotp
13、late, while cool, and a baseline analgesic response time is acquired several hoursbefore drug treatment and testing. Mice are injected with either vehicle (n=8), morphine (5 mg/kg, n=8 or 10mg/kg, n=8), Oliceridine (1.2 mg/kg, n=9) or PZM21 (10 mg/kg, n=8; 20 mg/kg, n=11; or 40 mg/kg, n=8).After inj
14、ection of drug, the analgesic effect expressed as percentage maximum possible effect (%MPE) ismeasured at 15, 30, 60, 90 and 120 min after drug treatment. If animals do not display hind paw lick, splay,or flutter, they are removed from the trial. Additionally, if animals attempt to jump out of the p
15、late or urinatedon the hotplate they are removed from the trial. To assess analgesia by the tail-flick assay, a tail-flickanalgesia meter. Mice are gently immobilized with a cotton towel and the tail base is placed on a radiant lightsource emitting a constant temperature of 56 C. The tail withdrawal
16、 latency is measured at similar timepoints as the hotplate assay after administration of vehicle (n=8), morphine (5 mg/kg, n=4; 10 mg/kg, n=8) orPZM21 (10 mg/kg, n=8; 20 mg/kg; n=14). The cut-off time for the heat source is set at 10 s to avoid tissuedamage. Analgesic response times are measured sim
17、ilar to the hotplate assayMCE has not independently confirmed the accuracy of these methods. They are for reference only.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEREFERENCES1. Altarifi AA, et al. Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (olicer
18、idine) on measuresof antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol. 2017 Jan 1:26988111662. DeWire SM, et al. A G protein-biased ligand at the -opioid receptor is potently analgesic with reduced gastrointestinal and respiratorydysfunction compared with morphine. J Pharmacol Exp Ther. 2013 Mar;344(3):708-17.3. Manglik A, et al. Structure-based discovery of opio
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年中國乳酸依沙吖啶溶液行業(yè)市場深度評估及投資方向研究報告
- 綢緞項目可行性研究報告
- 2025年度智能共享單車租賃平臺運營管理合同
- 2025年度智慧城市建設(shè)項目咨詢服務(wù)承攬合同模板
- 2025年度智慧醫(yī)療信息化系統(tǒng)承包合同范本
- 2025年度食品公司蔬菜種植基地病蟲害防治合同4篇
- 二零二五電商大數(shù)據(jù)分析平臺開發(fā)合同
- 二零二五年度汽車租賃與金融服務(wù)訂車合同
- 2025年度新能源電動汽車租賃與維護(hù)服務(wù)合同
- 2025年度城市綠化景觀設(shè)計與施工合同
- 2024年同等學(xué)力人員申請碩士學(xué)位英語試卷與參考答案
- 小學(xué)一年級數(shù)學(xué)20以內(nèi)的口算題(可直接打印A4)
- 自動化設(shè)備技術(shù)合作協(xié)議書范文
- SF-36生活質(zhì)量調(diào)查表(SF-36-含評分細(xì)則)
- 作文紙(網(wǎng)格600字A4)
- 幼兒園語言教育活動的特點
- 危險源辨識和控制措施..
- 桑-蠶-雞套養(yǎng)技術(shù)及效益分析
- 我愛你中國原版五線譜鋼琴譜正譜樂譜.docx
- 原子光譜的精細(xì)結(jié)構(gòu)
- QGDW 11860-2018 抽水蓄能電站項目后評價技術(shù)標(biāo)準(zhǔn)
評論
0/150
提交評論